1g05: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==HETEROCYCLE-BASED MMP INHIBITOR WITH P2'SUBSTITUENTS== | ==HETEROCYCLE-BASED MMP INHIBITOR WITH P2'SUBSTITUENTS== | ||
<StructureSection load='1g05' size='340' side='right' caption='[[1g05]], [[Resolution|resolution]] 2.45Å' scene=''> | <StructureSection load='1g05' size='340' side='right'caption='[[1g05]], [[Resolution|resolution]] 2.45Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[1g05]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1G05 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1G05 FirstGlance]. <br> | <table><tr><td colspan='2'>[[1g05]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1G05 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1G05 FirstGlance]. <br> | ||
| Line 32: | Line 32: | ||
</div> | </div> | ||
<div class="pdbe-citations 1g05" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 1g05" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[Matrix metalloproteinase|Matrix metalloproteinase]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
| Line 37: | Line 40: | ||
</StructureSection> | </StructureSection> | ||
[[Category: Human]] | [[Category: Human]] | ||
[[Category: Large Structures]] | |||
[[Category: Stromelysin 1]] | [[Category: Stromelysin 1]] | ||
[[Category: Almstead, N G]] | [[Category: Almstead, N G]] | ||
Revision as of 11:32, 23 October 2019
HETEROCYCLE-BASED MMP INHIBITOR WITH P2'SUBSTITUENTSHETEROCYCLE-BASED MMP INHIBITOR WITH P2'SUBSTITUENTS
Structural highlights
Disease[MMP3_HUMAN] Defects in MMP3 are the cause of susceptibility to coronary heart disease type 6 (CHDS6) [MIM:614466]. A multifactorial disease characterized by an imbalance between myocardial functional requirements and the capacity of the coronary vessels to supply sufficient blood flow. Decreased capacity of the coronary vessels is often associated with thickening and loss of elasticity of the coronary arteries. Note=A polymorphism in the MMP3 promoter region is associated with the risk of coronary heart disease and myocardial infarction, due to lower MMP3 proteolytic activity and higher extracellular matrix deposition in atherosclerotic lesions.[1] [2] Function[MMP3_HUMAN] Can degrade fibronectin, laminin, gelatins of type I, III, IV, and V; collagens III, IV, X, and IX, and cartilage proteoglycans. Activates procollagenase. Evolutionary Conservation Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf. Publication Abstract from PubMedPotent and selective inhibition of matrix metalloproteinases was demonstrated for a series of sulfonamide-based hydroxamic acids. The design of the heterocyclic sulfonamides incorporates a six- or seven-member central ring with a P2' substituent that can be modified. Binding interactions of this substituent at the S2' site are believed to contribute to high inhibitory potency against stromelysin, collagenase-3 and gelatinases A and B, and to provide selectivity against collagenase-1 and matrilysin. An X-ray structure of a stromelysin inhibitor complex was obtained to provide insights into the SAR and selectivity trends observed for the series. Heterocycle-based MMP inhibitors with P2' substituents.,Pikul S, Dunham KM, Almstead NG, De B, Natchus MG, Taiwo YO, Williams LE, Hynd BA, Hsieh LC, Janusz MJ, Gu F, Mieling GE Bioorg Med Chem Lett. 2001 Apr 23;11(8):1009-13. PMID:11327577[3] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||||